Brokerage firm Prabhudas Lilladher has maintained a 'BUY' rating on Cera Sanitaryware with a target price of Rs 7,221. While the company reported a strong 19.5% revenue growth in the first quarter of fiscal year 2027, profits declined due to temporary margin pressure. Investors are now focused on management's plans to recover profit margins by the third quarter through recent price increases and operational adjustments.
Prabhudas Lilladher has reaffirmed its 'BUY' rating on Cera Sanitaryware, setting a target price of Rs 7,221. This move comes following the company’s financial results for the first quarter of fiscal year 2027 (Q1 FY27), which highlighted a divergence between strong sales growth and short-term pressure on bottom-line profitability.
During Q1 FY27, Cera Sanitaryware reported standalone revenue of Rs 486 crore, a significant 19.5% increase compared to the same period last year. However, net profit for the quarter fell by 2.6% to Rs 45.31 crore. This decline occurred despite the higher revenue, as the company grappled with margin pressure.
Management attributed this profit dip to several temporary factors. These included a one-time wage settlement, increased employee benefit expenses, and higher raw material input costs that were not immediately offset by price adjustments. To protect its profit margins, the company has implemented cumulative price hikes, raising rates by 12% for its sanitaryware segment and 16% for its faucetware business.
Looking ahead, the company remains optimistic about its performance for the remainder of the fiscal year. Management has provided a revenue growth guidance of 18% to 20% for FY27. Furthermore, they expect EBITDA margins—a key measure of the company's core operating profitability—to recover to a range of 13.5% to 14% by the third quarter of the fiscal year as these one-time costs normalize and price increases take effect.
While the growth outlook appears positive, investors should be aware of potential risks. A slowdown in the broader economy could impact demand for both retail and project-based sanitaryware, potentially affecting sales volume. Additionally, the company faces execution risks as it works to integrate and absorb new brands like Senator and Polypluz into its existing distribution network. Operational challenges, such as potential supply chain disruptions or labor-related issues in manufacturing clusters, also remain a risk factor that could impact production consistency.
Moving forward, the key monitorable for investors will be whether the company can successfully defend its profit margins in the coming quarters and if the market accepts these recent price increases without a significant impact on demand.